Medicus Pharma Ltd. (MDCX)
| Market Cap | 85.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 11.73M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,641 |
| Open | 7.03 |
| Previous Close | 7.08 |
| Day's Range | 6.87 - 7.57 |
| 52-Week Range | 1.80 - 8.94 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 23.50 (+222.36%) |
| Earnings Date | May 12, 2025 |
About MDCX
Medicus Pharma Ltd., a biotech/life sciences company, focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is developing SkinJect, with an indication for basal cell carcinoma that is drug device combination product using novel dissolvable microneedle arrays for the treatment of non-melanoma skin cancers. Medicus Pharma Ltd. was founded in 2015 and is headquartered in Toronto, Canada. [Read more]
Analyst Forecast
According to 2 analysts, the average rating for MDCX stock is "Strong Buy." The 12-month stock price forecast is $23.5, which is an increase of 222.36% from the latest price.
News
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Med...
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev's issued and outstanding shares on a share exchange.
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class mark...
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, Penns...
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering...
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, o...
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or...
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) ...
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd.
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horse...
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile ...
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously ann...
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public...